661 related articles for article (PubMed ID: 34689859)
1. Effectiveness of bortezomib and temozolomide for eradication of recurrent human glioblastoma cells, resistant to radiation.
Pak O; Zaitsev S; Shevchenko V; Sharma A; Sharma HS; Bryukhovetskiy I
Prog Brain Res; 2021; 266():195-209. PubMed ID: 34689859
[TBL] [Abstract][Full Text] [Related]
2. Cytoplasmic Shotgun Proteomic Points to Key Proteins and Pathways in Temozolomide-Resistant Glioblastoma Multiforme.
Teraiya M; Krokhin O; Chen VC; Perreault H
J Proteome Res; 2024 Jan; 23(1):465-482. PubMed ID: 38147655
[TBL] [Abstract][Full Text] [Related]
3. Targeting the non-coding genome and temozolomide signature enables CRISPR-mediated glioma oncolysis.
Tan IL; Perez AR; Lew RJ; Sun X; Baldwin A; Zhu YK; Shah MM; Berger MS; Doudna JA; Fellmann C
Cell Rep; 2023 Nov; 42(11):113339. PubMed ID: 37917583
[TBL] [Abstract][Full Text] [Related]
4. Subclonal evolution and expansion of spatially distinct THY1-positive cells is associated with recurrence in glioblastoma.
Al-Holou WN; Wang H; Ravikumar V; Shankar S; Oneka M; Fehmi Z; Verhaak RG; Kim H; Pratt D; Camelo-Piragua S; Speers C; Wahl DR; Hollon T; Sagher O; Heth JA; Muraszko KM; Lawrence TS; de Carvalho AC; Mikkelsen T; Rao A; Rehemtulla A
Neoplasia; 2023 Feb; 36():100872. PubMed ID: 36621024
[TBL] [Abstract][Full Text] [Related]
5. Temozolomide and flavonoids against glioma: from absorption and metabolism to exosomal delivery.
Verma P; Joshi H; Singh T; Sharma B; Sharma U; Ramniwas S; Rana R; Gupta M; Kaur G; Tuli HS
Naunyn Schmiedebergs Arch Pharmacol; 2024 Jan; 397(1):41-57. PubMed ID: 37566307
[TBL] [Abstract][Full Text] [Related]
6. Proteasome Inhibitors against Glioblastoma-Overview of Molecular Mechanisms of Cytotoxicity, Progress in Clinical Trials, and Perspective for Use in Personalized Medicine.
Gozdz A
Curr Oncol; 2023 Nov; 30(11):9676-9688. PubMed ID: 37999122
[TBL] [Abstract][Full Text] [Related]
7. Synergistic Effect of a Combination of Proteasome and Ribonucleotide Reductase Inhibitors in a Biochemical Model of the Yeast
Kulagin KA; Starodubova ES; Osipova PJ; Lipatova AV; Cherdantsev IA; Poddubko SV; Karpov VL; Karpov DS
Int J Mol Sci; 2024 Apr; 25(7):. PubMed ID: 38612788
[TBL] [Abstract][Full Text] [Related]
8. Repurposing FDA-approved drugs as inhibitors of therapy-induced invadopodia activity in glioblastoma cells.
Jones D; Whitehead CA; Dinevska M; Widodo SS; Furst LM; Morokoff AP; Kaye AH; Drummond KJ; Mantamadiotis T; Stylli SS
Mol Cell Biochem; 2023 Jun; 478(6):1251-1267. PubMed ID: 36302993
[TBL] [Abstract][Full Text] [Related]
9. Targeted Sensitization of Glioblastoma Multiforme Using AAAPT Technology.
Mendieta M; Avci NG; Pandurangi R; Akay YM; Akay M
IEEE Open J Eng Med Biol; 2023; 4():251-258. PubMed ID: 38196976
[TBL] [Abstract][Full Text] [Related]
10. SapC-DOPS as a Novel Therapeutic and Diagnostic Agent for Glioblastoma Therapy and Detection: Alternative to Old Drugs and Agents.
Kaynak A; Davis HW; Vallabhapurapu SD; Pak KY; Gray BD; Qi X
Pharmaceuticals (Basel); 2021 Nov; 14(11):. PubMed ID: 34832975
[TBL] [Abstract][Full Text] [Related]
11. A designer peptide against the EAG2-Kvβ2 potassium channel targets the interaction of cancer cells and neurons to treat glioblastoma.
Dong W; Fekete A; Chen X; Liu H; Beilhartz GL; Chen X; Bahrampour S; Xiong Y; Yang Q; Zhao H; Kong T; Morioka MS; Jung G; Kim JE; Schramek D; Dirks PB; Song Y; Kim TH; He Y; Wanggou S; Li X; Melnyk RA; Wang LY; Huang X
Nat Cancer; 2023 Oct; 4(10):1418-1436. PubMed ID: 37697045
[TBL] [Abstract][Full Text] [Related]
12. The Role of Progranulin (PGRN) in the Pathogenesis of Glioblastoma Multiforme.
Poniatowski ŁA; Woźnica M; Wojdasiewicz P; Mela-Kalicka A; Romanowska-Próchnicka K; Purrahman D; Żurek G; Krawczyk M; Nameh Goshay Fard N; Furtak-Niczyporuk M; Jaroszyński J; Mahmoudian-Sani MR; Joniec-Maciejak I
Cells; 2024 Jan; 13(2):. PubMed ID: 38247816
[TBL] [Abstract][Full Text] [Related]
13. Proteomic and metabolomic signatures of U87 glioblastoma cells treated with cisplatin and/or paclitaxel.
Ahmed M; Semreen AM; Giddey AD; Ramadan WS; El-Awady R; Soares NC; El-Huneidi W; Bustanji Y; Alqudah MAY; Alzoubi KH; Semreen MH
Ann Med; 2023; 55(2):2305308. PubMed ID: 38253025
[TBL] [Abstract][Full Text] [Related]
14. Cilostazol eliminates radiation-resistant glioblastoma by re-evoking big conductance calcium-activated potassium channel activity.
Liu CC; Wu CL; Yeh IC; Wu SN; Sze CI; Gean PW
Am J Cancer Res; 2021; 11(4):1148-1169. PubMed ID: 33948351
[TBL] [Abstract][Full Text] [Related]
15. New Multitarget Approaches in the War Against Glioblastoma: A Mini-Perspective.
Sestito S; Runfola M; Tonelli M; Chiellini G; Rapposelli S
Front Pharmacol; 2018; 9():874. PubMed ID: 30123135
[TBL] [Abstract][Full Text] [Related]
16. Recurrent Glioblastoma: Where we stand.
Roy S; Lahiri D; Maji T; Biswas J
South Asian J Cancer; 2015; 4(4):163-73. PubMed ID: 26981507
[TBL] [Abstract][Full Text] [Related]
17. Advances and challenges in the molecular biology and treatment of glioblastoma-is there any hope for the future?
Veliz I; Loo Y; Castillo O; Karachaliou N; Nigro O; Rosell R
Ann Transl Med; 2015 Jan; 3(1):7. PubMed ID: 25705639
[TBL] [Abstract][Full Text] [Related]
18. An early and rare second malignancy in a treated glioblastoma multiforme: is it radiation or temozolomide?
Goyal S; Singh RR; Balukrishna S; Bindra M; Backianathan S
J Clin Diagn Res; 2015 Apr; 9(4):TD05-7. PubMed ID: 26023622
[TBL] [Abstract][Full Text] [Related]
19. Pediatric Glioblastoma Multiforme: A Challenging Case of Rapid Growth and Clinical Deterioration in an 11-Year-Old Female Patient.
I Kh Almadhoun MK; Hattab AAW
Cureus; 2023 Oct; 15(10):e47697. PubMed ID: 38021881
[TBL] [Abstract][Full Text] [Related]
20. Editorial: Metabolic reprogramming for acquiring therapeutic resistance in glioblastoma.
Hsu TI
Front Oncol; 2023; 13():1220063. PubMed ID: 37519794
[No Abstract] [Full Text] [Related]
[Next] [New Search]
